重组活化因子Ⅶ治疗创伤性失血的研究进展  

Research progress of recombinant activated factor Ⅶ for the treatment of traumatic hemorrhage

作　　者：冯筑生 尹文[1] 

机构地区：[1]第四军医大学西京医院急诊科,陕西西安710032

出　　处：《创伤外科杂志》2015年第3期281-283,共3页Journal of Traumatic Surgery

基　　金：国家自然科学基金资助项目(81070063);陕西省自然科学基金重点项目(2014JM4186)

摘　　要：严重创伤性失血患者死亡率很高,近年来涌现了许多旨在改善创伤后凝血功能和减少临床输血需求的新型辅助止血药物,重组活化因子Ⅶ(recombinant activated factorⅦ,r FⅦa)被批准应用于治疗血友病,现已拓展至创伤,并在救治钝挫伤、创伤伴凝血功能障碍和颅脑创伤等方面取得了一定进展,本文就r FⅦa治疗创伤性失血相关研究情况进行回顾,以期为临床和科研提供参考。The mortality of patients with severe traumatic hemorrhage is rather high.Many new adjunct he-mostatic agents for the improvement of the coagulation function and reduction of blood transfusion after trauma e-merge in recent years.Recombinant activated factorⅦ（ rFⅦa） which is approved for the treatment of hemophilia has been exposed to trauma, and some progress is made in blunt trauma, trauma patients with coagulopathy and craniocerebral trauma.This article reviews research progress of rFⅦa for traumatic hemorrhage which aims to pro-vide reference for clinical practice and scientific research.

关 键 词：创伤 失血 活化因子 

分 类 号：R64[医药卫生—外科学]